ContraVir Pharmaceuticals, Inc.
(NASDAQ : CTRV)

( )
CTRV After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
0.66%18.291.8%$101.14m
JAZZJazz Pharmaceuticals Plc
0.23%136.822.3%$71.45m
UTHRUnited Therapeutics Corporation
-1.17%76.3614.3%$70.77m
MDCOMedicines Company
2.84%34.7221.8%$62.00m
SAGESAGE Therapeutics, Inc.
-3.90%171.258.7%$60.80m
ARQLArQule, Inc.
-3.70%10.420.7%$59.96m
PRGOPerrigo Co. Plc
0.46%45.716.8%$53.91m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-1.80%168.706.2%$48.27m
ICPTIntercept Pharmaceuticals, Inc.
-0.75%77.7718.6%$44.94m
CTLTCatalent Inc
-0.34%52.982.4%$43.82m
HZNPHorizon Pharma plc
-1.01%23.646.7%$39.37m
ICLRICON Plc
1.38%150.004.1%$39.02m
MNKMallinckrodt Plc
1.19%8.5021.0%$27.95m
PTLAPortola Pharmaceuticals, Inc.
-0.47%25.647.5%$25.88m
ZYNEZynerba Pharmaceuticals Inc
-0.56%12.488.3%$25.09m

Company Profile

ContraVir Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.